Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials

Abstract

Men receiving androgen deprivation therapy (ADT) for prostate cancer (PCa) are likely to develop metabolic conditions such as diabetes, cardiovascular disease, abdominal obesity and osteoporosis. Other treatment-related side effects adversely influence quality of life (QoL) including vasomotor distress, depression, anxiety, mood swings, poor sleep quality and compromised sexual function. The objective of this study was to systematically review the nature and effects of dietary and exercise interventions on QoL, androgen deprivation symptoms and metabolic risk factors in men with PCa undergoing ADT. An electronic search of CINAHL, CENTRAL, Medline, PsychINFO and reference lists was performed to identify peer-reviewed articles published between January 2004 and December 2014 in English. Eligible study designs included randomised controlled trials (RCTs) with pre- and post-intervention data. Data extraction and assessment of methodological quality with the Cochrane approach was conducted by two independent reviewers. Seven exercise studies were identified. Exercise significantly improved QoL, but showed no effect on metabolic risk factors (weight, waist circumference, lean or fat mass, blood pressure and lipid profile). Two dietary studies were identified, both of which tested soy supplements. Soy supplementation did not improve any outcomes. No dietary counselling studies were identified. No studies evaluated androgen-deficiency symptoms (libido, erectile function, sleep quality, mood swings, depression, anxiety and bone mineral density). Evidence from RCTs indicates that exercise...
enhances health- and disease-specific QoL in men with PCa undergoing ADT. Further studies are required to evaluate the effect of exercise and dietary interventions on QoL, androgen deprivation symptoms and metabolic risk factors in this cohort.

Introduction
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men after lung cancers. According to the International Agency for Research on Cancer, more than 1.1 million cases were diagnosed in 2012, with highest incidence rates in Australia, New Zealand and Northern America followed by Western and Northern Europe (Ferlay et al. 2013).

Managing treatment-related morbidity is increasingly important for men undergoing androgen deprivation therapy (ADT). In hormone-sensitive PCa, androgens can stimulate the growth of cancer cells. These effects can be blocked or reduced through the use of surgical or medical ADT, shrinking the tumour or slowing tumour growth. This therapy is common for the management of metastatic PCa and as an adjuvant therapy in localised PCa. With the exception of primary ADT in men with localised PCa (Sammon et al. 2015), the use rates of ADT in Australia and the USA are rising, with this therapy being offered earlier in the cancer trajectory (Grossmann et al. 2011). Compared with no treatment, ADT is associated with an increased risk in non-cancer mortality in men over 66 years with localised disease (Abdollah et al. 2015). These men are more likely to develop metabolic conditions, such as diabetes, cardiovascular disease and abdominal obesity, or experience further life-limiting morbidities such as osteoporosis. Treatment-related side effects include vasomotor distress, depression and anxiety, mood swings, poor sleep quality and compromised libido and erectile function leading to diminished function and quality of life (QoL; Grossmann et al. 2011).

Evidence indicates that the effects of ADT can be attenuated through specific health behaviours. The current ‘Nutrition and physical activity guidelines for cancer survivors’ (Rock et al. 2012) recommend that for all cancers, nutrition, physical activity, stress and sleep assessment should commence as soon as possible after diagnosis, and account for current and anticipated preferences, symptoms and lifestyle needs. In cancer survivors, exercise has been shown to improve cardiovascular fitness, muscle strength, body composition, fatigue, anxiety, depression and some aspects of QoL (Rock et al. 2012). Similarly, an individualised multi-disciplinary approach including dietetics and exercise physiotherapy was recommended in the joint consensus statement from the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand (Grossmann et al. 2011).

In a previous meta-analysis, Chipperfield et al. (2014) evaluated the effect of physical activity on outcomes such as depression, anxiety, cognitive function and QoL while excluding studies of other outcomes or those including dietary interventions. There are no meta-analyses of high level evidence that evaluate the effect of dietary and/or exercise interventions in preventing or ameliorating ADT-related metabolic and other side effects beyond those relating to QoL.

The aim of this review is to examine the effectiveness of dietary and/or exercise in preventing, modifying or managing the effects of ADT in men with PCa. Specifically, the primary objective is to investigate the effect of these interventions on QoL, and the secondary objectives are to evaluate the effects on androgen deprivation symptoms and metabolic risk factors.

Materials and methods
Eligibility criteria
To address the review objectives, we included randomised controlled trials (RCTs) of adult male participants (>18 years of age) with PCa undergoing ADT. Studies with participants not undergoing ADT, and whose data were reported separately, were included. Interventions of interest compared aerobic exercise, resistance exercise and/or dietary counselling with standard care or no treatment. Dietary supplements were compared with matched placebo. Primary outcome measures were health-related QoL (overall physical or mental health) and disease-specific QoL (QoL in the context of PCa) as measured by validated questionnaires. Secondary outcome measures of androgen deprivation symptoms were dual X-ray absorptiometry (DXA) scans of bone mineral
density, vasomotor symptoms, insomnia and mood swings, weight gain, depression and anxiety. Secondary outcome measures of metabolic risk factors were fasting glucose, fasting lipid profile and/or fat mass measured by DXA.

Search methods
A search of Medline was undertaken (Table 1) to identify relevant text words and index terms used to describe the articles. A second search of CINAHL, Cochrane CENTRAL, Medline and PsychINFO was conducted using identified text words and index terms. Reference lists of relevant articles were hand searched for additional studies that met the inclusion criteria. Only articles published in the English language between 2004 and 2014 were included.

Data collection and extraction
One author (L Teleni) analysed the titles and abstracts from the searches. Full text was sought for studies that both potentially met the eligibility criteria and, where eligibility could not be determined due to insufficient information. Two authors (A L McCarthy and L Teleni) independently assessed eligibility from the full text; any disagreements were resolved by discussion and consensus.

Two review authors (A L McCarthy and L Teleni) independently extracted data from each study using a template developed by the authors for the purpose of the review. Data extracted included descriptions of general study information, methods, participants, intervention and comparator, outcomes and length of follow-up, study results for each outcome and time of assessment. Any discrepancies between review authors were discussed and corrected by consulting the original article. For studies published more than once, data was collated. Where data for an outcome was reported more than once, the data from the publication with the largest study population was used.

Assessment of risk or bias
Two review authors (A L McCarthy and L Teleni) independently assessed the risk of bias of the included studies using the Cochrane Collaboration’s tool for assessing risk of bias (Higgins & Green 2011). This tool assesses random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting. Each study was graded according to low, high or unclear risk of bias.

Statistical analysis
Where possible, data were used to calculate the mean difference (MD) using the mean for continuous outcomes with number of participants as the denominator for each outcome. Where different scales were used, the standardised MD (SMD) was calculated. Where the S.D. of the change scores was not given, they were imputed using the S.D. from similar studies (Higgins & Green 2011).

Obvious clinical heterogeneity was assessed by comparing populations, settings, interventions and outcomes before deciding whether it was appropriate to pool studies. Where pooling was undertaken, statistical heterogeneity was assessed with the I^2 statistic. Where it was reasonable to assume a single pooled effect (I^2<50%), a fixed-effect model was used. Where variation in populations and interventions or substantial heterogeneity (I^2≥50%) was evident, a random-effects model was used (DerSimonian & Laird 1986). Review Manager 5.3 was used for statistical analysis (RevMan version 5.3, The Table 1  

<table>
<thead>
<tr>
<th>Subject</th>
<th>MeSH and keywords</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate cancer</td>
<td>'Prostatic Neoplasms' (MeSH) or prostate cancer</td>
</tr>
<tr>
<td>Dietary interventions</td>
<td>‘Diet’ (MeSH) or ‘Diet Therapy’ (MeSH)</td>
</tr>
<tr>
<td>Dietary supplements</td>
<td>‘Isoflavones’ (MeSH) or isoflavones or ‘Flax’ (MeSH) or flaxseed or ‘Soy Milk’ (MeSH) or ‘Soy Foods’ (MeSH) or soy or ‘Soybean Proteins’ (MeSH) or ‘Carotenoids’ (MeSH) or ‘Vitamin E’ (MeSH) or lycopene or ‘Folic Acid’ (MeSH) or folate or ‘Dietary Supplements’ (MeSH) or ‘Complementary Therapies’ (MeSH) or ‘Naturopathy’ (MeSH)</td>
</tr>
<tr>
<td>Fruit, vegetables and fibre</td>
<td>‘Fruit’ (MeSH) or fruit or ‘Vegetables’ (MeSH) or vegetables or ‘Dietary Fiber’ (MeSH) or dietary fibre ‘Dairy Products’ (MeSH) or dairy or ‘Calcium, Dietary’ (MeSH) or ‘Meat’ (MeSH) or ‘Dietary Fats’ (MeSH)</td>
</tr>
<tr>
<td>Dairy, meat and fat</td>
<td>‘Exercise’ (MeSH) or ‘physical endurance’ (MeSH) or ‘Exercise Therapy’ (MeSH)</td>
</tr>
<tr>
<td>Exercise interventions</td>
<td>English language, 2004–current, all adult (19 + years)</td>
</tr>
<tr>
<td>Search limits</td>
<td></td>
</tr>
</tbody>
</table>
Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Where statistical pooling was not possible, findings are presented in narrative form.

**Results**

Of the 246 potential articles, 13 met the inclusion criteria (Fig. 1), providing data for nine intervention studies. Intervention characteristics and key findings are summarised in Table 2. The median sample size was 100 (33–121) participants with median intervention duration of 12 (12–24) weeks. Although participant eligibility criteria were similar, cancer stage and treatment varied between studies, as did the depth of information provided about these variables. Only three of the nine studies provided details on the duration of ADT (Fig. 2). As expected for lifestyle-based interventions, the largest risk of bias was lack of blinding of participants.

There were also studies that lacked adequate information for domains of risk of bias assessment. Lack of details pertaining to both random sequence generation and allocation of concealment potentially introduced selection bias. Where studies failed to report blinding of outcome assessors, they introduced potential detection bias. In addition, incomplete outcome data and selective reporting may have increased the risk of attrition and reporting bias.

Seven RCTs investigated the effects of exercise on QoL, androgen deprivation symptoms and/or metabolic risk factors in men with PCs (Segal et al. 2009, Culos-Reed et al. 2010, Galvao et al. 2010, 2014, Bourke et al. 2011, 2014, Alberga et al. 2012, Cormie et al. 2013, Uth et al. 2014). Four studies included intervention groups that combined resistance exercise training (RET) and aerobic exercise training (AET) (Galvao et al. 2010, 2014, Bourke et al. 2011, 2014), two studies used only RET (Segal et al. 2009, Culos-Reed et al. 2010, Alberga et al. 2012), one study used AET (Segal et al. 2009, Alberga et al. 2012) and one used football training sessions (Uth et al. 2014). Participants in the interventions involving AET, trained at an intensity ranging from 55 to 85% of maximal heart rate or 11–15 points on the Borg Rating of Perceived Exertion Scale. Most studies of RET did not report exercise intensity. Of those that did, participants trained at 60–70% of one repetition maximum.

Two dietary RCTs of 99 participants investigated the efficacy of 12 weeks of soy supplementation on QoL, androgen deprivation symptoms or metabolic risk factors in men with PCs (Sharma et al. 2009, Napora et al. 2011, Vitolins et al. 2013). One study had four treatment groups randomising venlafaxine and venlafaxine placebo as well as soy and soy placebo (Vitolins et al. 2013). For this review, we only included the treatment groups where venlafaxine placebos were used so as to compare the effects of soy supplementation.

**Interventions**

Quality of life

Health-related QoL was reported in five exercise studies of 427 participants (Culos-Reed et al. 2010, Galvao et al. 2010, 2014, Bourke et al. 2011, 2014, Alberga et al. 2012). Disease-specific QoL was reported in three exercise studies of 271 participants (Bourke et al. 2011, 2014, Alberga et al. 2012). There was no significant clinical or statistical heterogeneity ($I^2=0\%$) and the overall risk of bias was low. Quantitative analysis showed that exercise improved health-related QoL (SMD = 0.29; 95% CI = 0.10–0.49) and disease-specific QoL (SMD = 0.36; 95% CI = 0.11–0.61) in men with PCs undergoing ADT (Figs 3 and 4 respectively).

Health-related QoL was reported in both dietary intervention studies. There was no significant clinical or statistical heterogeneity ($I^2=0\%$) and the risk of bias was low. Soy supplementation did not significantly improve health-related QoL (SMD = 0.01; 95% CI = −0.38 to 0.41). Only Vitolins et al. (2013) evaluated disease-specific QoL,
Table 2  Study characteristics and key findings

<table>
<thead>
<tr>
<th>References</th>
<th>Design</th>
<th>Sample</th>
<th>Duration of ADT</th>
<th>Intervention duration and frequency</th>
<th>Intervention form and dose</th>
<th>Control</th>
<th>Key findings intervention vs control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bourke et al. (2011)</td>
<td>Two-arm</td>
<td>50</td>
<td>≥ 6 months</td>
<td>12 weeks; supervised 2 days/week (weeks 1–6)–1 day/week (weeks 7–12), unsupervised 1 day/week (weeks 1–6)–2 days/week (weeks 7–12); optional dietary counselling 1 day/fortnight</td>
<td>30 min supervised AET at 55–85% predicted MHR or 11–15 Borg Rating of Perceived Exertion Scale + two to four sets supervised RET + 30 min unsupervised exercise + optional 15–20 min small group dietary counselling</td>
<td>Usual care</td>
<td>↓ HRQoL&lt;sup&gt;a&lt;/sup&gt;  ↓ DQoLB&lt;sup&gt;b&lt;/sup&gt;  ↓ Fatigue&lt;sup&gt;c&lt;/sup&gt;  ↓ BW, BMI or WHR  ↓ Systolic or diastolic BP</td>
</tr>
<tr>
<td>Bourke et al. (2014)</td>
<td>Two-arm</td>
<td>100</td>
<td>33 ± 33 months (intervention), 30 ± 30 months (control)</td>
<td>12 weeks; supervised 2 days/week (weeks 1–6)–1 day/week (weeks 7–12), unsupervised 1 day/week (weeks 1–6)–2 days/week (weeks 7–12); dietary counselling 1 day/fortnight</td>
<td>30 min supervised AET at 55–75% predicted MHR or 11–13 Borg Rating of Perceived Exertion Scale + two to four sets of 8–12 repetitions of supervised RET (60% 1 RM) + 30 min unsupervised exercise + 20 min small group dietary counselling</td>
<td>Usual care</td>
<td>↑ DQoLB&lt;sup&gt;b&lt;/sup&gt;  ↓ Fatigue&lt;sup&gt;c&lt;/sup&gt;  ↓ BW or BMI  ↓ Systolic or diastolic BP</td>
</tr>
<tr>
<td>Culos-Reed et al. (2010)</td>
<td>Two-arm</td>
<td>100</td>
<td>≥ 6 months</td>
<td>16 weeks; supervised booster session 1 day/week unsupervised 3–5 days/week</td>
<td>Supervised and unsupervised exercise sessions of walking, stretching, ‘light’ RET. Supervised group sessions of 60 min exercise + 30 min education. Unsupervised ‘moderate’ exercise</td>
<td>Usual care</td>
<td>← QoL&lt;sup&gt;d&lt;/sup&gt;  ← Fatigue&lt;sup&gt;e&lt;/sup&gt;  ← Depression&lt;sup&gt;f&lt;/sup&gt;  ← Hormone symptoms&lt;sup&gt;g&lt;/sup&gt;  ← BMI  ↓ WC  ↓ Systolic or diastolic BP</td>
</tr>
<tr>
<td>Galvao et al. (2010) and Cormie et al. (2013)</td>
<td>Two-arm</td>
<td>57</td>
<td>≥ 2 months</td>
<td>12 weeks; supervised 2 days/week + unsupervised 150 min/week</td>
<td>Two to four sets of supervised RET (12–6 RM) in small groups+15–20 min supervised AET at 65–80% MHR and 11–13 Borg Rating of Perceived Exertion Scale + unsupervised AET</td>
<td>Usual care</td>
<td>↑ QoL&lt;sup&gt;h&lt;/sup&gt;  ↓ Libido, urinary or bowel symptoms&lt;sup&gt;i&lt;/sup&gt;  ↓ BW  ↑ kg LBM&lt;sup&gt;j&lt;/sup&gt;  ↔ kg FM or % FM&lt;sup&gt;i&lt;/sup&gt;  ↔ Glucose, TC, TG, LDL or HDL  ↓ TC  ↓ HDL  ↔ Glucose, TG or LDL  ↔ Systolic or diastolic BP</td>
</tr>
<tr>
<td>Galvao et al. (2014)</td>
<td>Two-arm</td>
<td>100</td>
<td>Not reported</td>
<td>24 weeks; supervised 2 days/week, unsupervised 2 days/week</td>
<td>Supervised, small group, two to four sets RET (12–16 RM)+20–30 min AET at 70–85% MHR and 11–13 Borg Rating of Perceived Exertion Scale + unsupervised AET</td>
<td>Usual care+ pedometer and modified educational booklet</td>
<td>UP QoL&lt;sup&gt;h&lt;/sup&gt;  ↓ BW or WC  ↔ kg LBM, kg FM or % FM&lt;sup&gt;i&lt;/sup&gt;  ↓ TC  ↓ HDL  ↔ Glucose, TG or LDL  ↔ Systolic or diastolic BP</td>
</tr>
<tr>
<td>References</td>
<td>Design</td>
<td>Sample</td>
<td>Duration of ADT</td>
<td>Intervention duration and frequency</td>
<td>Intervention form and dose</td>
<td>Control</td>
<td>Key findings intervention vs control</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
<td>--------</td>
<td>-----------------</td>
<td>-------------------------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Segal et al. (2009) and Alberg et al. (2012)</td>
<td>Three-arm</td>
<td>121</td>
<td>102.9 ± 166.3 days</td>
<td>24 weeks; 3 days/week</td>
<td>Two sets supervised RET, 8–12 repetitions at 60–70% of 1 RM, 15–45 min supervised AET at 50–60%–70–75% MHR</td>
<td>Usual care</td>
<td>RET: ↔ HRQoL&lt;sup&gt;a&lt;/sup&gt; ↔ DQoL&lt;sup&gt;b&lt;/sup&gt; ↓ Fatigue&lt;sup&gt;c&lt;/sup&gt; ↔ BW or BMI ↓ % FM&lt;sup&gt;d&lt;/sup&gt; ↑ kg LBM&lt;sup&gt;e&lt;/sup&gt; AET: ↔ HRQoLa ↔ DQoLb ↔ Fatiguec ↔ BW ↓ BMI ↔ kg LBM or % FM↓ ↔ HRQoLa ↔ BW or BMI ↔ Libido or erectile function&lt;sup&gt;l&lt;/sup&gt; ↔ Sleep quality&lt;sup&gt;m&lt;/sup&gt; ↑ Hot flashes&lt;sup&gt;n&lt;/sup&gt; ↔ Glucose, TC, TG and HDL or LDL</td>
</tr>
<tr>
<td>Sharma et al. (2009) and Napora et al. (2011)</td>
<td>Two-arm</td>
<td>33</td>
<td>≥ 3 months</td>
<td>12 weeks; 1/day</td>
<td>20 g powder soy protein, total isoflavones (64 mg genistein, 63 mg daidzein and 34 mg glycitein) mixed in beverage</td>
<td>Usual care</td>
<td>HRQoL&lt;sup&gt;a&lt;/sup&gt; ↔ DQoL&lt;sup&gt;b&lt;/sup&gt; ↔ Fatigue&lt;sup&gt;c&lt;/sup&gt; ↔ BW ↓ BMI ↔ kg LBM or % FM↓ ↔ HRQoLa ↔ BW or BMI ↔ Libido or erectile function&lt;sup&gt;k,l&lt;/sup&gt; ↔ Sleep quality&lt;sup&gt;m&lt;/sup&gt; ↑ Hot flashes&lt;sup&gt;n&lt;/sup&gt; ↔ Glucose, TC, TG and HDL or LDL</td>
</tr>
<tr>
<td>Uth et al. (2014)</td>
<td>Two-arm</td>
<td>57</td>
<td>≥ 6 months</td>
<td>12 weeks; 2 days/week (weeks 1–8) and 3 days/week (weeks 9–12)</td>
<td>15 min warm up + two to three 15-min football games</td>
<td>Usual care</td>
<td>kg LBM↓ ↔ kg FM or % FM↓ ↔ WHR ↓ HRQoL&lt;sup&gt;a&lt;/sup&gt; ↔ DQoL&lt;sup&gt;b&lt;/sup&gt; ↔ Hot flashes&lt;sup&gt;g&lt;/sup&gt;</td>
</tr>
<tr>
<td>Vitolins et al. (2013)</td>
<td>Four-arm</td>
<td>120</td>
<td>12 weeks; 1 day</td>
<td>Placebo venlafaxine + 20 g powder soy protein (160 mg isoflavones)</td>
<td>Placebo venlafaxine + 20 g milk powder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ADT, androgen deprivation therapy; RET, resistance exercise training; AET, aerobic exercise training; RM, repetition maximum; MHR, maximal heart rate; HRQoL, health-related quality of life; DQoL, disease-specific quality of life; BW, body weight; WHR, waist:hip ratio; LBM, lean body mass; FM, fat mass; BP, blood pressure; WC, waist circumference; TC, total cholesterol; TG, triglycerides.

<sup>a</sup>FACT-G, Functional Assessment of Cancer Therapy–general.

<sup>b</sup>FACT-P, FACT-prostate.

<sup>c</sup>FACT-F, FACT-fatigue.

<sup>d</sup>EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer quality of life questionnaire.

<sup>e</sup>ESS, fatigue.

<sup>f</sup>CES-D, Centers for Epidemiologic Studies–Depression.

<sup>g</sup>HFSS, Hot Flash Symptom Severity Score.

<sup>h</sup>SF-36, 36-item Short-Form Health Survey, general score.

<sup>i</sup>EORTC QLQ-PR25, EORTC Prostate Cancer-Specific Quality of Life Questionnaire.

<sup>j</sup>DXA, dual X-ray absorptiometry.

<sup>k</sup>Watts questionnaire.

<sup>l</sup>Index of Erectile Function.

<sup>m</sup>Epsworth Sleepiness Scale.

<sup>n</sup>Blatt–Kupperman.
reporting that soy supplementation significantly improved FACT-P global score vs placebo (112.5 ± 6.0 vs 103.8 ± 6.2, \( P = 0.048 \)).

**Androgen deprivation symptoms**

No exercise intervention evaluated libido, erectile function, sleep quality and insomnia, mood swings, depression or anxiety or bone mineral density. Both dietary intervention studies evaluated the effect of soy supplementation on vasomotor distress. Sharma *et al.* (2009) reported a significant difference in hot flash scores between groups, but within-group analysis showed no significant improvement in vasomotor distress score in either the placebo or the soy arms due to the imbalance in scores at baseline. Similarly, Vitolins *et al.* (2013) found soy supplementation did not significantly improve hot flash number, severity or hot flash score vs placebo. One dietary intervention study evaluated libido, erectile function and sleep quality but found no significant improvements with soy supplementation (Sharma *et al.* 2009, Napora *et al.* 2011). No dietary studies evaluated insomnia, mood swings, depression, anxiety or bone mineral density.
Exercise did not significantly improve any body composition measure including lean body mass (MD = –0.20; 95% CI = –1.72 to 1.32; Galvao et al. 2010, 2014, Alberga et al. 2012, Uth et al. 2014), total fat mass (MD = –0.61; 95% CI = –2.48 to 1.26; Galvao et al. 2010, 2014, Uth et al. 2014) or percentage fat mass (MD = –0.71; 95% CI = –1.96 to 0.55; Galvao et al. 2010, 2014, Alberga et al. 2012, Uth et al. 2014).

One dietary intervention study evaluated body weight and BMI but found no significant improvements with soy supplementation (Sharma et al. 2009, Napora et al. 2011). Neither dietary intervention evaluated the effect of soy supplementation on body composition.

Three intervention studies with a combined total of 300 participants reported that exercise did not significantly improve systolic blood pressure (MD = 1.72; 95% CI = –2.47 to 5.90; Culos-Reed et al. 2010, Galvao et al. 2010, Bourke et al. 2014). Similarly, exercise did not significantly improve blood glucose levels (MD = 0.13; 95% CI = –0.16 to 0.43), total cholesterol (MD = 0.13; 95% CI = –0.18 to 0.44), triglycerides (MD = –0.06; 2014).
95% CI = −0.27 to 0.15), LDL cholesterol (MD = 0.06; 95% CI = −0.20 to 0.32) or HDL cholesterol (MD = 0.06; 95% CI = −0.05 to 0.16).

Only one dietary intervention study evaluated the effect of soy supplementation on lipid profile. Soy supplementation did not significantly improve total cholesterol, triglycerides, LDL cholesterol or HDL cholesterol. Neither dietary supplement studies evaluated the effect of soy on glucose levels.

**Discussion**

**Exercise**

Exercise interventions conducted over 12–24 weeks and which consisted of two to three days per week of combined aerobic and resistance exercise, were associated with significant improvements in health- and disease-specific QoL in men with PCa receiving ADT. Despite these improvements, the magnitude of effect of exercise on these outcomes was small to moderate. The majority of included studies implemented resistance and aerobic exercise as a combined intervention, so it was not possible to determine whether this improvement was attributable to the one type of exercise or the synergy of both. These results are consistent with the meta-analysis by Chipperfield et al. (2014) who reported preliminary data indicating that physical activity significantly improved QoL. However, in the present analysis there were no corresponding improvements in any secondary outcomes. A possible explanation lies in the studies’ designs. Exercise intervention studies are often at much greater risk of performance bias compared with other randomised trial designs due to the use of usual care or waitlist control groups, as well as the logistical inability to blind participants and interventionists. Moreover, those in the exercise groups had longer and more intense contact with interventionists, a degree of health professional contact that could have improved perceptions of QoL independent of the effect of exercise. Therefore, improvements in these outcomes may have been masked by a variability in the types of exercise, intensity of the intervention and the duration of the interventions.

Bone fracture is a major risk factor for increased mortality. Depleted testosterone and oestrogen levels in men with PCa undergoing ADT can lead to bone loss (Higano 2004). These changes increase bone resorption and suppress bone formation, increasing the risk of fracture (Higano 2008, Michaud 2010). Despite the well-established effect of ADT on bone mineral density, there were a notable lack of studies evaluating the effect of exercise on this outcome. Similarly, other androgen deficiency symptoms including hot flashes, sexual function, sleep quality, depression and anxiety were often not reported as outcomes. These findings are consistent with Chipperfield et al. (2014) who also identified no studies evaluating the effect of physical activity on anxiety and depression.

Although ADT is associated with reduced PCa-specific mortality, its association with increased risk of non-cancer mortality, metabolic parameters and body composition could lead to the development of metabolic syndrome. Metabolic syndrome is a cluster of cardiovascular risk factors including insulin resistance, increased triglycerides and fasting glucose, low HDL, increased waist circumference and hypertension. It is implicated in the development of diabetes and cardiovascular disease. In addition to metabolic syndrome, large cohort analyses have demonstrated that serum cholesterol is independently associated with cardiovascular mortality (Stamler et al. 1986, Lewington et al. 2007).

Interestingly, although associated with the development of diabetes (Saylor & Smith 2009), the effect of ADT on the risk of developing cardiovascular disease is unclear. ADT increases a number of cardiovascular risk factors, including elevated fasting insulin; decreased insulin sensitivity; worsened lipid profile (Whitsel et al. 2001, Isidori et al. 2005, Laughlin et al. 2008, Traish et al. 2009); hypertension (Svarthberg et al. 2004) and abdominal obesity (Marin et al. 1993). In a large meta-analysis of observational studies, Zhao et al. (2014) reported a non-significant 10% increase in cardiovascular disease risk (hazard ratio (HR) = 1.10; 95% CI = 1.00–1.21; P = 0.06) but a significant association with cardiovascular mortality (HR = 1.17; 95% CI = 1.04–1.32; P = 0.01). Conversely, in a meta-analysis of RCTs (Nguyen et al. 2011), the relative risk of cardiovascular death for men undergoing ADT for PCa vs control was not significant (risk ratio (RR) = 0.93; 95% CI = 0.79–1.10; P = 0.41). The discrepancy between these two analyses could be explained by differences in risk. Compared with patients with more advanced disease, low risk patients have a higher life expectancy and are less likely to die of their cancer and therefore live long enough for cardiovascular disease to become a problem.

We found that exercise did not significantly improve lipid profiles, blood glucose levels, blood pressure, body weight or body composition. It is possible that too few studies were included in the current meta-analysis, thereby providing insufficient data or sample size to
identify any ameliorative effect of exercise on these outcomes.

Weight gain in men undergoing ADT for PCa over 12–24 weeks would likely be minimal. Seible et al. (2014) reported that even one year after ADT initiation, weight gain was clinically insignificant (1.32 ± 4 kg, *P* = 0.0005). Contrary to traditional beliefs about risk groups, Seible et al. (2014) has previously reported that the independent predictors of weight gain in this population include a non-obese BMI and a relatively young age (i.e. < 30 kg/m² and < 65 years old respectively). The mean sample ages of the studies analysed in this review were over 65 years, with most centring around 70 years. The inclusion of studies of older populations could have unintentionally obfuscated any larger weight alterations in the younger participants, resulting in smaller mean weight changes.

It is also possible that any losses in fat mass may have been obscured by gains in lean tissue. In men undergoing ADT, significant weight and body composition changes tend to occur within the first few months of treatment initiation and continue for 1–2 years. In an observational study, Smith et al. (2002) reported that men undergoing 48 weeks of ADT experienced significant increases in percentage body fat (9.4 ± 1.7%, *P* < 0.001) and significant decreases in percentage lean body mass (2.7 ± 0.5%, *P* < 0.001). In the current study, despite most studies’ eligibility criteria including men who had been undergoing ADT for at least 2–6 months, exercise did not significantly improve fat mass or lean body mass. However, similar to weight changes, it is possible that too few studies were included in the current analysis to capture such small changes or that intervention periods were too short to capture the effect of exercise on body composition.

**Diet**

The precise contribution of sex steroid deprivation to the adverse effects of ADT is unclear. Low testosterone has been implicated in diminished QoL, androgen-deficiency symptoms and metabolic risk factors in men with PCa on ADT; however, these men also have low oestradiol levels (Sharma et al. 2009). It is hypothesised that due to the structural similarity of isoflavones (soy protein) to oestrogen, soy could induce a weak oestrogenic effect, minimising these adverse effects. In this review, soy supplementation did not significantly improve health-related QoL and there were insufficient data to quantitatively address disease-specific QoL. There were also insufficient data to evaluate the effect of soy on androgen deficiency symptoms, with the exception of vasomotor distress. Consistent with previous trials, soy supplementation did not significantly improve vasomotor distress. In breast cancer, soy has been shown to have no effect on the menopausal symptoms of postmenopausal women (Quella et al. 2000, Van Patten et al. 2002, MacGregor et al. 2005). There were insufficient data to evaluate the effect of soy on metabolic risk factors.

**Strengths and limitations**

This systematic review includes a quantitative analysis of RCTs, the highest level of evidence for interventions. Where studies were combined, there was minimal clinical and statistical heterogeneity. Data extraction and risk of bias assessment was conducted independently by two reviewers and almost all studies were found to have a low risk of bias.

The findings of this review were limited, however, by the lack of dietary intervention studies, particularly those using dietary counselling. Exercise interventions could not be evaluated by exercise type (i.e. resistance vs aerobic) so any significant results should be considered preliminary and attributed to combined modality.

**Conclusion**

There are significant gaps in the literature with regards to dietary and exercise interventions for the management of QoL, androgen deficiency symptoms and metabolic risk factors in men receiving ADT for PCa. Although the effects of exercise interventions on QoL are apparent, it is unclear whether these improvements are attributable to increased interventionist contact, aerobic exercise, resistance exercise or the combination of all three. More studies are required that control for interventionist contact as well as exercise type (i.e. aerobic or resistance), intensity and duration.

There is also a clear gap in the literature as to the effect of dietary counselling on QoL, androgen deficiency symptoms and metabolic risk factors in men undergoing ADT. No dietary studies addressing the effects of dietary counselling on ADT symptom management were identified for this review. It is possible that either the dietary counselling studies are addressing outcomes which have little relevance to ADT symptom management or they do not exist.

Despite the findings of this review, interventions that are effective in this population are still needed to ameliorate or manage the adverse effects of ADT. This is
particularly important for decreasing this risk of cardiovascular disease and diabetes through managing metabolic risk factors and addressing bone mineral density.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the New Professor Grant, Queensland University of Technology.

Author contribution statement
A L McCarthy conceptualised the systematic review. A L McCarthy and L Teleni designed the systematic review and collected the data. L Teleni, A L McCarthy and R J Chan performed the initial analysis and interpretation and wrote the manuscript. All authors reviewed the analysis, interpretation and critically reviewed the manuscript. All authors have read and approved the version of the manuscript being submitted.

References
Alberga AS, Segal RJ, Reid RD, Scott CG, Sigal RJ, Khandwala F, Jaffey J, Abdollah F, Sammon JD, Reznor G, Sood A, Schmid M, Klett DE, Sun M, the version of the manuscript being submitted.

Endocrine-Related Cancer

DOI: 10.1530/ERC-15-0456

http://erc.endocrinology-journals.org

Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 04/02/2019 07:20:31PM via free access
Endocrine-Related Cancer


Received in final form 16 November 2015
Accepted 19 November 2015
Made available online as an Accepted Preprint 19 November 2015